In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 111 to 120 of 301

TitleTypeExpected publication date
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidanceTBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]Technology appraisal guidanceTBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidance
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidanceTBC
Insulin efsitora alfa for treating type 2 diabetes [ID6499]Technology appraisal guidance
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All